Plasminogen activator inhibitor type-1 gene 4G/5G polymorphism in Turkish adult patients with asthma.

AIM: This study has been performed on asthmatic patients in the Turkish population to determine the frequency of 4G/5G polymorphism genotypes of plasminogen activator inhibitor type-1 gene, and with the aim of examining the role of this polymorphism in asthma development. METHODS: Genomic DNA obtained from 165 persons (98 patients with asthma and 67 healthy controls) was used in the study. DNA was multiplied with polymerase chain reaction using 4G and 5G allele-specific primers. Polymerase chain reaction products were assessed with CCD camera by being exposed to 2% agarose gel electrophoresis. Results were evaluated with chi-square test. RESULTS: No statistically significant difference between the groups with respect to genotype distribution was found (p > 0.05) in the study. The 4G allele frequency was indicated as 48% and 5G allele was as 52% in patients, whereas this was 50-50% in the control group. CONCLUSION: It has been established by this study that 4G/5G polymorphism genotypes of plasminogen activator inhibitor type-1 gene do not play a role in the development of asthma in the Turkish population.

Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke.

AIM: This study was carried out to determine if there is any association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism and plasma PAI-1 enzyme activity in acute stroke patients. METHODS: In this study, 333 genomic DNAs (from 253 acute stroke patients and 80 healthy subjects) were analyzed. Genomic DNAs were prepared from peripheral blood using a saline method. These DNAs were amplified by PCR method using primers specific for 4G and 5G alleles. PCR products were separated by 2% agarose gel electrophoresis and visualized by a charge coupled device (CCD) camera. PAI-1 enzyme activities were measured by ELISA method. The results were evaluated statistically with Student's t-test, chi(2)-test, one-way analysis of variance, and stepwise regression analysis. RESULTS: In this study, frequency of PAI-1 gene 4G5G genotype was found to be low both in patients and controls. PAI-1 enzyme activities were significantly increased in acute stroke patients compared to controls. Although PAI-1 gene 4G5G genotype frequencies were low, the patients carrying this allele had highest plasma PAI-1 enzyme activity; likewise, although PAI-1 gene 4G4G genotype frequencies were high, the patients carrying this allele had lowest plasma PAI-1 enzyme activities. Homocysteine levels had a positive effect of 65% on plasma PAI-1 enzyme activities. CONCLUSION: Consequently, in this study, we may assert that PAI-1 gene, 4G4G and 5G5G genotypes, PAI-1 activity, and homocysteine level determination are significant criteria for identifying patients who are likely to develop stroke; on the other hand, a direct relation does not exist between gene polymorphism and enzyme activity.